Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/262128 
Authors: 
Year of Publication: 
2022
Series/Report no.: 
Research Paper No. 153
Publisher: 
South Centre, Geneva
Abstract: 
This report provides an analysis of patents covering medicines in trials to treat COVID-19. The aim of the report is to support national patent offices and interested parties in developing countries with information that can serve as guidance for the examination of the claims contained in relevant patents or patent applications. The medicines considered for the patent analysis in this report are remdesivir, ruxolitinib, favipiravir, molnupiravir and nirmatrelvir, and the biotherapeutics tocilizumab, siltuximab and sarilumab.
Subjects: 
Access to Medicines
Affordable Medicines
Biotherapeutics
Coronavirus
COVID-19
Favipiravir
Global Health
Health
Intellectual Property
Molnupiravir
Nirmatrelvir
Pandemic
Patent
Patent Offices
Public Health
Remdesivir
Ruxolitinib
Sarilumab
Siltuximab
Tocilizumab
Document Type: 
Research Report
Appears in Collections:

Files in This Item:
File
Size
4.96 MB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.